Johnson & Johnson $JNJ Stake Decreased by PFG Investments LLC

Key Points

• PFG Investments reduced its Johnson & Johnson stake by 3.5% in the second quarter, selling 3,720 shares and retaining 101,254 shares worth approximately $25.7 million. Institutional investors and hedge funds collectively own 69.55% of JNJ.
• Johnson & Johnson reported quarterly EPS of $2.90, exceeding estimates, while revenue rose 6.6% year over year to $25.31 billion. The company declared a $1.34 quarterly dividend, equivalent to a 2.0% annual yield.
• JNJ shares opened at $271.05, near their 52-week high, and analysts maintain a consensus “Moderate Buy” rating with an average price target of $268.22. Several executives have recently sold shares, including more than 63,000 shares collectively during the last quarter.

PFG Investments LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 101,254 shares of the company's stock after selling 3,720 shares during the period. Johnson & Johnson makes up about 1.0% of PFG Investments LLC's investment portfolio, making the stock its 17th largest holding. PFG Investments LLC's holdings in Johnson & Johnson were worth $25,716,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in JNJ. World Investment Advisors increased its stake in Johnson & Johnson by 19.6% during the 4th quarter. World Investment Advisors now owns 161,343 shares of the company's stock valued at $33,390,000 after buying an additional 26,450 shares during the period. Benchmark Financial LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $554,000. Principal Financial Group Inc. boosted its holdings in shares of Johnson & Johnson by 0.8% in the fourth quarter. Principal Financial Group Inc. now owns 3,410,177 shares of the company's stock valued at $705,736,000 after acquiring an additional 28,370 shares in the last quarter. SageGuard Financial Group LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $1,019,000. Finally, Signal Advisors Wealth LLC raised its holdings in Johnson & Johnson by 76.1% during the first quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company's stock worth $3,697,000 after purchasing an additional 6,539 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the firm's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the transaction, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the transaction, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 63,972 shares of company stock worth $16,245,605. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Trading Up 3.3%

Johnson & Johnson stock opened at $271.05 on Wednesday. The firm has a market cap of $653.20 billion, a price-to-earnings ratio of 31.41, a price-to-earnings-growth ratio of 2.48 and a beta of 0.24. Johnson & Johnson has a 1 year low of $173.33 and a 1 year high of $274.90. The firm's 50 day moving average price is $253.21 and its two-hundred day moving average price is $241.91. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. The company had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The company's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, research analysts predict that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be given a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson's dividend payout ratio (DPR) is 62.11%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Morgan Stanley upped their target price on Johnson & Johnson from $284.00 to $294.00 and gave the stock an "overweight" rating in a research report on Thursday, July 16th. Weiss Ratings raised Johnson & Johnson from a "buy (b-)" rating to a "buy (b)" rating in a research note on Friday, July 24th. Wall Street Zen lowered Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Freedom Capital raised Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 16th. Finally, Bank of America lifted their target price on Johnson & Johnson from $254.00 to $263.00 and gave the stock a "neutral" rating in a report on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $268.22.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA clearance strengthens the MedTech growth story. The FDA cleared J&J’s AI-powered MONARCH QUEST 3 bronchoscopy update, which adds planning, navigation and imaging capabilities to the company’s robotic lung-diagnostics platform. The authorization could support broader adoption and reinforce J&J’s push into robotic and advanced surgical technologies. J&J secures FDA clearance for MONARCH QUEST 3
• Positive Sentiment: Strong results and raised guidance continue to support the stock. J&J reported second-quarter revenue of $25.31 billion, up 6.6% year over year, and raised its 2026 outlook. Adjusted EPS of $2.90 exceeded the $2.84 consensus estimate, while revenue also topped expectations. Johnson & Johnson Stock Jumps as Healthcare Rotation Lifts Shares
• Positive Sentiment: Investors see replacement growth for Stelara. J&J’s immunology and neuroscience portfolios are emerging as important growth engines, with newer medicines helping offset the impact of Stelara’s loss of exclusivity. J&J’s New Growth Powerhouses
• Neutral Sentiment: Call-option activity rose above average, suggesting increased short-term bullish positioning, although options flows can add volatility without indicating durable fundamental demand.
• Negative Sentiment: Executive Vice President Jennifer Taubert sold 15,000 shares for approximately $3.95 million. The sale reduced her holdings by 7.16%; recurring insider selling across several executives may temper sentiment, though it does not necessarily signal a change in business prospects. SEC insider transaction filing

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source